Apellis Pharmaceuticals (NASDAQ:APLS) PT Lowered to $102.00

Apellis Pharmaceuticals (NASDAQ:APLSGet Rating) had its price objective dropped by Raymond James from $114.00 to $102.00 in a research note issued on Thursday, The Fly reports. Raymond James’ price target points to a potential upside of 121.98% from the stock’s previous close.

Several other analysts have also weighed in on the stock. Robert W. Baird lifted their target price on shares of Apellis Pharmaceuticals from $83.00 to $90.00 and gave the company an “outperform” rating in a research report on Wednesday, March 16th. Citigroup reiterated a “focus list” rating and set a $81.00 target price on shares of Apellis Pharmaceuticals in a research report on Thursday, March 17th. Roth Capital lowered shares of Apellis Pharmaceuticals from a “neutral” rating to a “sell” rating and set a $40.00 target price on the stock. in a research report on Wednesday, April 13th. The Goldman Sachs Group decreased their target price on shares of Apellis Pharmaceuticals from $102.00 to $86.00 and set a “buy” rating on the stock in a research report on Monday, March 7th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Apellis Pharmaceuticals from $66.00 to $69.00 and gave the company an “overweight” rating in a research report on Monday, April 4th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $69.87.

NASDAQ:APLS opened at $45.95 on Thursday. The firm’s 50-day moving average is $48.91 and its 200-day moving average is $44.06. Apellis Pharmaceuticals has a 52-week low of $27.50 and a 52-week high of $73.00. The company has a debt-to-equity ratio of 0.95, a quick ratio of 6.13 and a current ratio of 6.25. The company has a market cap of $4.89 billion, a price-to-earnings ratio of -5.15 and a beta of 1.63.

Apellis Pharmaceuticals (NASDAQ:APLSGet Rating) last posted its quarterly earnings data on Monday, February 28th. The company reported ($1.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.32) by ($0.29). The firm had revenue of $60.29 million for the quarter, compared to the consensus estimate of $8.52 million. During the same quarter last year, the firm posted $0.93 EPS. Equities analysts predict that Apellis Pharmaceuticals will post -5.22 EPS for the current year.

In other news, insider Pascal Deschatelets sold 4,000 shares of the company’s stock in a transaction that occurred on Friday, April 29th. The shares were sold at an average price of $44.43, for a total transaction of $177,720.00. Following the transaction, the insider now directly owns 891,775 shares in the company, valued at $39,621,563.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Alec Machiels sold 1,250 shares of the company’s stock in a transaction that occurred on Tuesday, March 15th. The stock was sold at an average price of $39.57, for a total transaction of $49,462.50. The disclosure for this sale can be found here. Insiders have sold 49,666 shares of company stock worth $2,466,491 over the last quarter. 9.50% of the stock is owned by company insiders.

Several institutional investors and hedge funds have recently bought and sold shares of APLS. Morgan Stanley raised its stake in shares of Apellis Pharmaceuticals by 50.9% during the second quarter. Morgan Stanley now owns 229,341 shares of the company’s stock worth $14,494,000 after buying an additional 77,317 shares during the last quarter. Raymond James Financial Services Advisors Inc. raised its stake in shares of Apellis Pharmaceuticals by 20.2% during the third quarter. Raymond James Financial Services Advisors Inc. now owns 16,136 shares of the company’s stock worth $532,000 after buying an additional 2,714 shares during the last quarter. Advisor Group Holdings Inc. raised its stake in shares of Apellis Pharmaceuticals by 80.8% during the third quarter. Advisor Group Holdings Inc. now owns 4,001 shares of the company’s stock worth $132,000 after buying an additional 1,788 shares during the last quarter. Russell Investments Group Ltd. raised its stake in shares of Apellis Pharmaceuticals by 63.1% during the third quarter. Russell Investments Group Ltd. now owns 124,434 shares of the company’s stock worth $4,099,000 after buying an additional 48,126 shares during the last quarter. Finally, Swiss National Bank raised its stake in shares of Apellis Pharmaceuticals by 0.4% during the third quarter. Swiss National Bank now owns 133,400 shares of the company’s stock worth $4,397,000 after buying an additional 500 shares during the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.

Apellis Pharmaceuticals Company Profile (Get Rating)

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases.

See Also

The Fly logo

Analyst Recommendations for Apellis Pharmaceuticals (NASDAQ:APLS)

Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.